TocilizumabV1, Main, Exploration, bibRecord, 000B89

Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

Identifieur interne : 000B89 ( Main/Exploration ); précédent : 000B88; suivant : 000B90

Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

Auteurs : Juan Shan [République populaire de Chine] ; Jiabi Zhang [République populaire de Chine]

Source :

Joint bone spine [ 1778-7254 ] ; 2019.

RBID : pubmed:29635017

Descripteurs français

KwdFr :
- Abatacept (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Arthrite psoriasique (traitement médicamenteux), Arthrite psoriasique (épidémiologie), Comorbidité, Femelle, Humains, Inflammation (traitement médicamenteux), Inflammation (épidémiologie), Maladie de Crohn (traitement médicamenteux), Maladie de Crohn (épidémiologie), Mâle, Obésité (diagnostic), Obésité (épidémiologie), Pelvispondylite rhumatismale (traitement médicamenteux), Pelvispondylite rhumatismale (épidémiologie), Polyarthrite rhumatoïde (traitement médicamenteux), Polyarthrite rhumatoïde (épidémiologie), Produits biologiques (pharmacologie), Produits biologiques (usage thérapeutique), Pronostic, Résultat thérapeutique, Évaluation des risques.
MESH :
- diagnostic : Obésité.
- pharmacologie : Produits biologiques.
- traitement médicamenteux : Arthrite psoriasique, Inflammation, Maladie de Crohn, Pelvispondylite rhumatismale, Polyarthrite rhumatoïde.
- usage thérapeutique : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Produits biologiques.
- épidémiologie : Arthrite psoriasique, Inflammation, Maladie de Crohn, Obésité, Pelvispondylite rhumatismale, Polyarthrite rhumatoïde.
- Comorbidité, Femelle, Humains, Mâle, Pronostic, Résultat thérapeutique, Évaluation des risques.

English descriptors

KwdEn :
- Abatacept (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Psoriatic (drug therapy), Arthritis, Psoriatic (epidemiology), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (epidemiology), Biological Products (pharmacology), Biological Products (therapeutic use), Comorbidity, Crohn Disease (drug therapy), Crohn Disease (epidemiology), Female, Humans, Inflammation (drug therapy), Inflammation (epidemiology), Male, Obesity (diagnosis), Obesity (epidemiology), Prognosis, Risk Assessment, Spondylitis, Ankylosing (drug therapy), Spondylitis, Ankylosing (epidemiology), Treatment Outcome.
MESH :
- chemical , pharmacology : Biological Products.
- chemical , therapeutic use : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products.
- diagnosis : Obesity.
- drug therapy : Arthritis, Psoriatic, Arthritis, Rheumatoid, Crohn Disease, Inflammation, Spondylitis, Ankylosing.
- epidemiology : Arthritis, Psoriatic, Arthritis, Rheumatoid, Crohn Disease, Inflammation, Obesity, Spondylitis, Ankylosing.
- Comorbidity, Female, Humans, Male, Prognosis, Risk Assessment, Treatment Outcome.

Abstract

Obesity is a worldwide epidemic and a growing body of evidence suggests that it may affect the body's response to biologic agents. We investigated the influence of obesity on the efficacy of different biologic agents used to treat inflammatory diseases.

DOI: 10.1016/j.jbspin.2018.03.007
PubMed: 29635017

Affiliations:

République populaire de Chine

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.</title>
<author><name sortKey="Shan, Juan" sort="Shan, Juan" uniqKey="Shan J" first="Juan" last="Shan">Juan Shan</name>
<affiliation wicri:level="1"><nlm:affiliation>Chengdu medical college, No. 783 XinDu Road, Chengdu, 610500 Sichuan Province, PR China. Electronic address: 30988978@qq.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Chengdu medical college, No. 783 XinDu Road, Chengdu, 610500 Sichuan Province</wicri:regionArea>
<wicri:noRegion>610500 Sichuan Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, Jiabi" sort="Zhang, Jiabi" uniqKey="Zhang J" first="Jiabi" last="Zhang">Jiabi Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province</wicri:regionArea>
<wicri:noRegion>610041 Sichuan Province</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:29635017</idno>
<idno type="pmid">29635017</idno>
<idno type="doi">10.1016/j.jbspin.2018.03.007</idno>
<idno type="wicri:Area/PubMed/Corpus">000792</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000792</idno>
<idno type="wicri:Area/PubMed/Curation">000792</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000792</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000447</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000447</idno>
<idno type="wicri:Area/Ncbi/Merge">001A29</idno>
<idno type="wicri:Area/Ncbi/Curation">001A29</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001A29</idno>
<idno type="wicri:Area/Main/Merge">000B89</idno>
<idno type="wicri:Area/Main/Curation">000B89</idno>
<idno type="wicri:Area/Main/Exploration">000B89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.</title>
<author><name sortKey="Shan, Juan" sort="Shan, Juan" uniqKey="Shan J" first="Juan" last="Shan">Juan Shan</name>
<affiliation wicri:level="1"><nlm:affiliation>Chengdu medical college, No. 783 XinDu Road, Chengdu, 610500 Sichuan Province, PR China. Electronic address: 30988978@qq.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Chengdu medical college, No. 783 XinDu Road, Chengdu, 610500 Sichuan Province</wicri:regionArea>
<wicri:noRegion>610500 Sichuan Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, Jiabi" sort="Zhang, Jiabi" uniqKey="Zhang J" first="Jiabi" last="Zhang">Jiabi Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province</wicri:regionArea>
<wicri:noRegion>610041 Sichuan Province</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Joint bone spine</title>
<idno type="eISSN">1778-7254</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antirheumatic Agents (therapeutic use)</term>
<term>Arthritis, Psoriatic (drug therapy)</term>
<term>Arthritis, Psoriatic (epidemiology)</term>
<term>Arthritis, Rheumatoid (drug therapy)</term>
<term>Arthritis, Rheumatoid (epidemiology)</term>
<term>Biological Products (pharmacology)</term>
<term>Biological Products (therapeutic use)</term>
<term>Comorbidity</term>
<term>Crohn Disease (drug therapy)</term>
<term>Crohn Disease (epidemiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Inflammation (drug therapy)</term>
<term>Inflammation (epidemiology)</term>
<term>Male</term>
<term>Obesity (diagnosis)</term>
<term>Obesity (epidemiology)</term>
<term>Prognosis</term>
<term>Risk Assessment</term>
<term>Spondylitis, Ankylosing (drug therapy)</term>
<term>Spondylitis, Ankylosing (epidemiology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antirhumatismaux (usage thérapeutique)</term>
<term>Arthrite psoriasique (traitement médicamenteux)</term>
<term>Arthrite psoriasique (épidémiologie)</term>
<term>Comorbidité</term>
<term>Femelle</term>
<term>Humains</term>
<term>Inflammation (traitement médicamenteux)</term>
<term>Inflammation (épidémiologie)</term>
<term>Maladie de Crohn (traitement médicamenteux)</term>
<term>Maladie de Crohn (épidémiologie)</term>
<term>Mâle</term>
<term>Obésité (diagnostic)</term>
<term>Obésité (épidémiologie)</term>
<term>Pelvispondylite rhumatismale (traitement médicamenteux)</term>
<term>Pelvispondylite rhumatismale (épidémiologie)</term>
<term>Polyarthrite rhumatoïde (traitement médicamenteux)</term>
<term>Polyarthrite rhumatoïde (épidémiologie)</term>
<term>Produits biologiques (pharmacologie)</term>
<term>Produits biologiques (usage thérapeutique)</term>
<term>Pronostic</term>
<term>Résultat thérapeutique</term>
<term>Évaluation des risques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Biological Products</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Antirheumatic Agents</term>
<term>Biological Products</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Obesity</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Obésité</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Psoriatic</term>
<term>Arthritis, Rheumatoid</term>
<term>Crohn Disease</term>
<term>Inflammation</term>
<term>Spondylitis, Ankylosing</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Arthritis, Psoriatic</term>
<term>Arthritis, Rheumatoid</term>
<term>Crohn Disease</term>
<term>Inflammation</term>
<term>Obesity</term>
<term>Spondylitis, Ankylosing</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Produits biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite psoriasique</term>
<term>Inflammation</term>
<term>Maladie de Crohn</term>
<term>Pelvispondylite rhumatismale</term>
<term>Polyarthrite rhumatoïde</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Antirhumatismaux</term>
<term>Produits biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Arthrite psoriasique</term>
<term>Inflammation</term>
<term>Maladie de Crohn</term>
<term>Obésité</term>
<term>Pelvispondylite rhumatismale</term>
<term>Polyarthrite rhumatoïde</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Comorbidity</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Prognosis</term>
<term>Risk Assessment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Comorbidité</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Résultat thérapeutique</term>
<term>Évaluation des risques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Obesity is a worldwide epidemic and a growing body of evidence suggests that it may affect the body's response to biologic agents. We investigated the influence of obesity on the efficacy of different biologic agents used to treat inflammatory diseases.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Shan, Juan" sort="Shan, Juan" uniqKey="Shan J" first="Juan" last="Shan">Juan Shan</name>
</noRegion>
<name sortKey="Zhang, Jiabi" sort="Zhang, Jiabi" uniqKey="Zhang J" first="Jiabi" last="Zhang">Jiabi Zhang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29635017
   |texte=   Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29635017" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.